USA: +1 347 690-0211 | UK: +44 2032 894158 | Translate :

Search Market Research Report

Discover Our Latest Reports

Discover Our Featured Reports

Discover Top Selling Reports

RNAi for the Therapeutics Market Size, Share Global Analysis Report, 2019 – 2026

Name: RNAi for the Therapeutics Market by Type (siRNA, miRNA, and shRNA), and By Sales Channel (Direct & Distributor) for Cancer, Ocular Disorder, HBV and Others: Global Industry Perspective, Comprehensive Analysis and Forecast 2019 – 2026
Creator: Facts and Factors
License: https://www.fnfresearch.com/privacy-policy

Press Release

Global RNAi for Therapeutics Market Revenue Projected Around USD 2,493.73 Million by 2026

RNAi for the Therapeutics Market by Type (siRNA, miRNA, and shRNA), and By Sales Channel (Direct & Distributor) for Cancer, Ocular Disorder, HBV and Others: Global Industry Perspective, Comprehensive Analysis and Forecast 2019 – 2026

Industry Insights

The report encompasses the forecast as well as an analysis of the RNAi for the Therapeutics market on the global and regional levels. The study displays historical data from 2016 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Million). Additionally, the market growth drivers, opportunities, limitations, and trends are also included in the RNAi for Therapeutic market report.

We have included industry analysis models in our report and extensively demonstrated the key business strategies and competitive landscape of the RNAi for the Therapeutics market in our study.

RNAi for the Therapeutics Market Size

To know more about this report | Request Free Sample Copy

Key Insights from Primary Research

As per our primary respondents, the China RNAi for the Therapeutic market is around USD 27Million in 2018
It was established through primary research that the EuropeRNAi for Therapeutics market was valued at more than USD 70million in 2019
The siRNA, on the basis of product type, was the leading revenue-generating category accounting for more than two-thirds of the total market, in 2019.

Key Recommendations from Analysts

As per our analysis, siRNA for Therapeutic is an attractive segment for the RNAi Therapeutics market. The product has a high demand for Cancer Therapy
Growing at a CAGR of around 18.91%, Asia PacificRNAi for Therapeutic market accounts for numerous opportunities for all of the investors
Our analysts have identified, maximum patients of Cancers are being treated by using RNAi techniques.

Global Bone Void Filler Market Analysis: By Region

RNAi for the Therapeutics Market

To know more about this report | Request Free Sample Copy

Our study also includes an analysis of Porter’s Five Forces framework for understanding the competitive strategies used by market competitors. It also encompasses PESTLE analysis and SWOT analysis.

The report also offers an in-depth analysis of the market share of each industry player and gives an outline of the market position of key players in the RNAi for the Therapeutics market. Moreover, the study offers wide coverage of key strategic improvements witnessed in the market such as acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, R&D activities, and geographical expansion of key players of the RNAi for the Therapeutics market.

The study provides a decisive view of the RNAi for the Therapeutics market by segmenting the RNAi for the Therapeutics market based on type, sales channel, application, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2020 to 2026. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The global RNAi for the Therapeutics market is experiencing vibrant growth that is expected to continue over the upcoming years. Cancer associated with the Geriatric population across the world is likely to act as a key driver of the global RNAi for the Therapeutics market.

The RNAi for the Therapeutics market is segmented based on type, application, and region. Type-wise, the market is classified into siRNA, miRNA, and shRNA. In terms of application, the market segment is sectored into Cancer, Ocular Disorders, HBV, and Others.

Report Scope

Report Attribute	Details
Market Size in 2019	USD 27 Million
Projected Market Size in 2026	USD 70 million
CAGR Growth Rate	18.91% CAGR
Base Year	2019
Forecast Years	2020-2026
Key Market Players	Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Quark Pharmaceuticals, RXi Pharmaceuticals, miRagen Therapeutics, Gradalis, Sirnaomics, and Others
Key Segment	By Type, By Application, By Distribution, By Region
Major Regions Covered	North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Purchase Options	Request customized purchase options to meet your research needs. Explore purchase options

This report segments the global RNAi for the Therapeutics market as follows:

Major Key market players are

Alnylam Pharmaceuticals
Arrowhead
Dicerna Pharmaceuticals
Quark Pharmaceuticals
RXi Pharmaceuticals
miRagen Therapeutics
Gradalis
Sirnaomics

Type Analysis

siRNA
miRNA
shRNA

Application Analysis

Cancer
Ocular Disorder
HBV
Others

Distribution Analysis

Direct Channel
Distributor Channel

Regional Analysis

North America
- U.S
- Canada
Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-East Asia
- Rest of Asia pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East and Africa
- GCC Countries
- South Africa
- Rest of the Middle East & Africa

Key Pointers Addressed by the Report

Historical data and forecast analysis of the market
Drivers and Restraints affecting market dynamics
Exhaustive analysis of the future market trends
Comprehensive information about the leading market segments and region
Strategic developments made by the competitive players and in-depth analysis of its impact on market growth

Table of Content

CHAPTER 1. Executive Summary
CHAPTER 2. RNAi for Therapeutic market – Product Analysis
1. 2.1. Global RNAi for Therapeutic Market – Product Overview
2. 2.2. Global RNAi for Therapeutic Market Share, by Product , 2016 & 2026 (USD Million)
3. 2.3. Global RNAi for Therapeutic Market share, by Product , 2016 & 2026 (K Unit)
4. 2.4. siRNA
  1. 2.4.1. Global siRNA RNAi for Therapeutic Market, 2016-2026 (USD Million)
  2. 2.4.2. Global siRNA RNAi for Therapeutic Market, 2016-2026 (K Unit)
5. 2.5. miRNA
  1. 2.5.1. Global miRNA RNAi for Therapeutic Market, 2016-2026 (USD Million)
  2. 2.5.2. Global miRNA RNAi for Therapeutic Market, 2016-2026 (K Unit)
6. 2.6. shRNA
  1. 2.6.1. Global shRNA RNAi for Therapeutic Market, 2016-2026 (USD Million)
  2. 2.6.2. Global shRNA RNAi for Therapeutic Market, 2016-2026 (K Unit)
CHAPTER 3. RNAi for Therapeutic market – Application Analysis
1. 3.1. Global RNAi for Therapeutic Market – Application Overview
2. 3.2. Global RNAi for Therapeutic Market Share, by Application, 2016 & 2026 (USD Million)
3. 3.3. Global RNAi for Therapeutic Market share, by Application, 2016 & 2026 (K Unit)
4. 3.4. Cancer
  1. 3.4.1. Global Cancer RNAi for Therapeutic Market, 2016-2026 (USD Million)
  2. 3.4.2. Global Cancer RNAi for Therapeutic Market, 2016-2026 (K Unit)
5. 3.5. Ocular Disorder
  1. 3.5.1. Global Ocular Disorder RNAi for Therapeutic Market, 2016-2026 (USD Million)
  2. 3.5.2. Global Ocular Disorder RNAi for Therapeutic Market, 2016-2026 (K Unit)
6. 3.6. HBV
  1. 3.6.1. Global HBV RNAi for Therapeutic Market, 2016-2026 (USD Million)
  2. 3.6.2. Global HBV RNAi for Therapeutic Market, 2016-2026 (K Unit)
7. 3.7. Others
  1. 3.7.1. Global Others RNAi for Therapeutic Market, 2016-2026 (USD Million)
  2. 3.7.2. Global Others RNAi for Therapeutic Market, 2016-2026 (K Unit)
CHAPTER 4. RNAi for Therapeutic market – Sales Channel Analysis
1. 4.1. Global RNAi for Therapeutic Market – Sales Channel Overview
2. 4.2. Global RNAi for Therapeutic Market Share, by Sales Channel, 2016 & 2026 (USD Million)
3. 4.3. Global RNAi for Therapeutic Market share, by Sales Channel, 2016 & 2026 (K Unit)
4. 4.4. Direct Channel
  1. 4.4.1. Global Direct Channel RNAi for Therapeutic Market, 2016-2026 (USD Million)
  2. 4.4.2. Global Direct Channel RNAi for Therapeutic Market, 2016-2026 (K Unit)
5. 4.5. Distribution Channel
  1. 4.5.1. Global Distribution Channel RNAi for Therapeutic Market, 2016-2026 (USD Million)
  2. 4.5.2. Global Distribution Channel RNAi for Therapeutic Market, 2016-2026 (K Unit)
CHAPTER 5. RNAi for Therapeutic market – Regional Analysis
1. 5.1. Global RNAi for Therapeutic Market Regional Overview
2. 5.2. Global RNAi for Therapeutic Market Share, by Region, 2016 & 2026 (Value)
3. 5.3. Global RNAi for Therapeutic Market Share, by Region, 2016 & 2026 (Volume)
4. 5.4. North America
  1. 5.4.1. North America RNAi for Therapeutic Market size and forecast, 2016-2026
  2. 5.4.2. North America RNAi for Therapeutic Market, by Country, 2018 - 2025 (USD Million)
  3. 5.4.3. North America Market size and forecast, 2016-2026 (K Unit)
  4. 5.4.4. North America RNAi for Therapeutic Market, by Country, 2018 - 2025 (K Unit)
  5. 5.4.5. North America RNAi for Therapeutic Market, by Product , 2016-2026
    1. 5.4.5.1. North America RNAi for Therapeutic Market, by Product , 2016-2026 (USD Million)
    2. 5.4.5.2. North America RNAi for Therapeutic Market, by Product , 2016-2026 (K Unit)
  6. 5.4.6. North America RNAi for Therapeutic Market, by Application, 2016-2026
    1. 5.4.6.1. North America RNAi for Therapeutic Market, by Application, 2016-2026 (USD Million)
    2. 5.4.6.2. North America RNAi for Therapeutic Market, by Application, 2016-2026 (K Unit)
  7. 5.4.7. North America RNAi for Therapeutic Market, by Sales Channel, 2016-2026
    1. 5.4.7.1. North America RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (USD Million)
    2. 5.4.7.2. North America RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (K Unit)
  8. 5.4.8. U.S.
    1. 5.4.8.1. U.S. Market size and forecast, 2016-2026 (USD Million)
    2. 5.4.8.2. U.S. Market size and forecast, 2016-2026 (K Unit)
  9. 5.4.9. Canada
    1. 5.4.9.1. Canada Market size and forecast, 2016-2026 (USD Million)
    2. 5.4.9.2. Canada Market size and forecast, 2016-2026 (K Unit)
5. 5.5. Europe
  1. 5.5.1. Europe RNAi for Therapeutic Market size and forecast, 2016-2026
  2. 5.5.2. Europe RNAi for Therapeutic Market, by Country, 2018 - 2025 (USD Million)
  3. 5.5.3. Europe Market size and forecast, 2016-2026 (K Unit)
  4. 5.5.4. Europe RNAi for Therapeutic Market, by Country, 2018 - 2025 (K Unit)
  5. 5.5.5. Europe RNAi for Therapeutic Market, by Product , 2016-2026
    1. 5.5.5.1. Europe RNAi for Therapeutic Market, by Product , 2016-2026 (USD Million)
    2. 5.5.5.2. Europe RNAi for Therapeutic Market, by Product , 2016-2026 (K Unit)
  6. 5.5.6. Europe RNAi for Therapeutic Market, by Application, 2016-2026
    1. 5.5.6.1. Europe RNAi for Therapeutic Market, by Application, 2016-2026 (USD Million)
    2. 5.5.6.2. Europe RNAi for Therapeutic Market, by Application, 2016-2026 (K Unit)
  7. 5.5.7. Europe RNAi for Therapeutic Market, by Sales Channel, 2016-2026
    1. 5.5.7.1. Europe RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (USD Million)
    2. 5.5.7.2. Europe RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (K Unit)
  8. 5.5.8. Germany
    1. 5.5.8.1. Germany Market size and forecast, 2016-2026 (USD Million)
    2. 5.5.8.2. Germany Market size and forecast, 2016-2026 (K Unit)
  9. 5.5.9. France
    1. 5.5.9.1. France Market size and forecast, 2016-2026 (USD Million)
    2. 5.5.9.2. France Market size and forecast, 2016-2026 (K Unit)
  10. 5.5.10. U.K.
    1. 5.5.10.1. U.K. Market size and forecast, 2016-2026 (USD Million)
    2. 5.5.10.2. U.K. Market size and forecast, 2016-2026 (K Unit)
  11. 5.5.11. Italy
    1. 5.5.11.1. Italy Market size and forecast, 2016-2026 (USD Million)
    2. 5.5.11.2. Italy Market size and forecast, 2016-2026 (K Unit)
  12. 5.5.12. Spain
    1. 5.5.12.1. Spain Market size and forecast, 2016-2026 (USD Million)
    2. 5.5.12.2. Spain Market size and forecast, 2016-2026 (K Unit)
  13. 5.5.13. Rest of Europe
    1. 5.5.13.1. Rest of Europe Market size and forecast, 2016-2026 (USD Million)
    2. 5.5.13.2. Rest of Europe Market size and forecast, 2016-2026 (K Unit)
6. 5.6. Asia Pacific
  1. 5.6.1. Asia Pacific RNAi for Therapeutic Market size and forecast, 2016-2026
  2. 5.6.2. Asia Pacific RNAi for Therapeutic Market, by Country, 2018 - 2025 (USD Million)
  3. 5.6.3. Asia Pacific Market size and forecast, 2016-2026 (K Unit)
  4. 5.6.4. Asia Pacific RNAi for Therapeutic Market, by Country, 2018 - 2025 (K Unit)
  5. 5.6.5. Asia Pacific RNAi for Therapeutic Market, by Product , 2016-2026
    1. 5.6.5.1. Asia Pacific RNAi for Therapeutic Market, by Product , 2016-2026 (USD Million)
    2. 5.6.5.2. Asia Pacific RNAi for Therapeutic Market, by Product , 2016-2026 (K Unit)
  6. 5.6.6. Asia Pacific RNAi for Therapeutic Market, by Application, 2016-2026
    1. 5.6.6.1. Asia Pacific RNAi for Therapeutic Market, by Application, 2016-2026 (USD Million)
    2. 5.6.6.2. Asia Pacific RNAi for Therapeutic Market, by Application, 2016-2026 (K Unit)
  7. 5.6.7. Asia Pacific RNAi for Therapeutic Market, by Sales Channel, 2016-2026
    1. 5.6.7.1. Asia Pacific RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (USD Million)
    2. 5.6.7.2. Asia Pacific RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (K Unit)
  8. 5.6.8. China
    1. 5.6.8.1. China Market size and forecast, 2016-2026 (USD Million)
    2. 5.6.8.2. China Market size and forecast, 2016-2026 (K Unit)
  9. 5.6.9. Japan
    1. 5.6.9.1. Japan Market size and forecast, 2016-2026 (USD Million)
    2. 5.6.9.2. Japan Market size and forecast, 2016-2026 (K Unit)
  10. 5.6.10. India
    1. 5.6.10.1. India Market size and forecast, 2016-2026 (USD Million)
    2. 5.6.10.2. India Market size and forecast, 2016-2026 (K Unit)
  11. 5.6.11. South Korea
    1. 5.6.11.1. South Korea Market size and forecast, 2016-2026 (USD Million)
    2. 5.6.11.2. South Korea Market size and forecast, 2016-2026 (K Unit)
  12. 5.6.12. South-East Asia
    1. 5.6.12.1. South-East Asia Market size and forecast, 2016-2026 (USD Million)
    2. 5.6.12.2. South-East Asia Market size and forecast, 2016-2026 (K Unit)
  13. 5.6.13. Rest of Asia Pacific
    1. 5.6.13.1. Rest of Asia Pacific Market size and forecast, 2016-2026 (USD Million)
    2. 5.6.13.2. Rest of Asia Pacific Market size and forecast, 2016-2026 (K Unit)
7. 5.7. Latin America
  1. 5.7.1. Latin America RNAi for Therapeutic Market size and forecast, 2016-2026
  2. 5.7.2. Latin America RNAi for Therapeutic Market, by Country, 2018 - 2025 (USD Million)
  3. 5.7.3. Latin America Market size and forecast, 2016-2026 (K Unit)
  4. 5.7.4. Latin America RNAi for Therapeutic Market, by Country, 2018 - 2025 (K Unit)
  5. 5.7.5. Latin America RNAi for Therapeutic Market, by Product , 2016-2026
    1. 5.7.5.1. Latin America RNAi for Therapeutic Market, by Product , 2016-2026 (USD Million)
    2. 5.7.5.2. Latin America RNAi for Therapeutic Market, by Product , 2016-2026 (K Unit)
  6. 5.7.6. Latin America RNAi for Therapeutic Market, by Application, 2016-2026
    1. 5.7.6.1. Latin America RNAi for Therapeutic Market, by Application, 2016-2026 (USD Million)
    2. 5.7.6.2. Latin America RNAi for Therapeutic Market, by Application, 2016-2026 (K Unit)
  7. 5.7.7. Latin America RNAi for Therapeutic Market, by Sales Channel, 2016-2026
    1. 5.7.7.1. Latin America RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (USD Million)
    2. 5.7.7.2. Latin America RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (K Unit)
  8. 5.7.8. Brazil
    1. 5.7.8.1. Brazil Market size and forecast, 2016-2026 (USD Million)
    2. 5.7.8.2. Brazil Market size and forecast, 2016-2026 (K Unit)
  9. 5.7.9. Mexico
    1. 5.7.9.1. Mexico Market size and forecast, 2016-2026 (USD Million)
    2. 5.7.9.2. Mexico Market size and forecast, 2016-2026 (K Unit)
  10. 5.7.10. Rest of Latin America
    1. 5.7.10.1. Rest of Latin America Market size and forecast, 2016-2026 (USD Million)
    2. 5.7.10.2. Rest of Latin America Market size and forecast, 2016-2026 (K Unit)
8. 5.8. The Middle-East and Africa
  1. 5.8.1. The Middle-East and Africa RNAi for Therapeutic Market size and forecast, 2016-2026
  2. 5.8.2. The Middle-East and Africa RNAi for Therapeutic Market, by Country, 2018 - 2025 (USD Million)
  3. 5.8.3. The Middle-East and Africa Market size and forecast, 2016-2026 (K Unit)
  4. 5.8.4. The Middle-East and Africa RNAi for Therapeutic Market, by Country, 2018 - 2025 (K Unit)
  5. 5.8.5. The Middle-East and Africa RNAi for Therapeutic Market, by Product , 2016-2026
    1. 5.8.5.1. The Middle-East and Africa RNAi for Therapeutic Market, by Product , 2016-2026 (USD Million)
    2. 5.8.5.2. The Middle-East and Africa RNAi for Therapeutic Market, by Product , 2016-2026 (K Unit)
  6. 5.8.6. The Middle-East and Africa RNAi for Therapeutic Market, by Application, 2016-2026
    1. 5.8.6.1. The Middle-East and Africa RNAi for Therapeutic Market, by Application, 2016-2026 (USD Million)
    2. 5.8.6.2. The Middle-East and Africa RNAi for Therapeutic Market, by Application, 2016-2026 (K Unit)
  7. 5.8.7. The Middle-East and Africa RNAi for Therapeutic Market, by Sales Channel, 2016-2026
    1. 5.8.7.1. The Middle-East and Africa RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (USD Million)
    2. 5.8.7.2. The Middle-East and Africa RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (K Unit)
  8. 5.8.8. GCC Countries
    1. 5.8.8.1. GCC Countries Market size and forecast, 2016-2026 (USD Million)
    2. 5.8.8.2. GCC Countries Market size and forecast, 2016-2026 (K Unit)
  9. 5.8.9. South Africa
    1. 5.8.9.1. South Africa Market size and forecast, 2016-2026 (USD Million)
    2. 5.8.9.2. South Africa Market size and forecast, 2016-2026 (K Unit)
  10. 5.8.10. Rest of Middle-East Africa
    1. 5.8.10.1. Rest of Middle-East Africa Market size and forecast, 2016-2026 (USD Million)
    2. 5.8.10.2. Rest of Middle-East Africa Market size and forecast, 2016-2026 (K Unit)
CHAPTER 6. RNAi for Therapeutic Production, Consumption, Export, Import by Regions
1. 6.1. Global RNAi for Therapeutic production and revenue, 2016-2026 (USD Million) (K Unit)
2. 6.2. Global Import and Export Analysis, by Region
CHAPTER 7. RNAi for Therapeutic market – Competitive Landscape
1. 7.1. Competitor Market Share – Revenue
2. 7.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
3. 7.3. Competitor Market Share – Volume
4. 7.4. Strategic Development
  1. 7.4.1. Acquisitions and Mergers
  2. 7.4.2. New Products
  3. 7.4.3. Research & Development Activities
CHAPTER 8. Company Profiles
1. 8.1. Alnylam Pharmaceuticals
  1. 8.1.1. Company Overview
  2. 8.1.2. Alnylam Pharmaceuticals Sales, Revenue, Price, and Gross Margin
  3. 8.1.3. Product portfolio
  4. 8.1.4. Recent initiatives
2. 8.2. Arrowhead Pharmaceuticals, Inc
  1. 8.2.1. Company Overview
  2. 8.2.2. Arrowhead Pharmaceuticals, Inc Sales, Revenue, Price, and Gross Margin
  3. 8.2.3. Product portfolio
  4. 8.2.4. Recent initiatives
3. 8.3. Dicerna Pharmaceuticals, Inc
  1. 8.3.1. Company Overview
  2. 8.3.2. Dicerna Pharmaceuticals, Inc Sales, Revenue, Price, and Gross Margin
  3. 8.3.3. Product portfolio
  4. 8.3.4. Recent initiatives
4. 8.4. Quark Pharmaceuticals
  1. 8.4.1. Company Overview
  2. 8.4.2. Quark Pharmaceuticals Sales, Revenue, Price, and Gross Margin
  3. 8.4.3. Product portfolio
  4. 8.4.4. Recent initiatives
5. 8.5. RXi Pharmaceuticals
  1. 8.5.1. Company Overview
  2. 8.5.2. RXi Pharmaceuticals Sales, Revenue, Price, and Gross Margin
  3. 8.5.3. Product portfolio
  4. 8.5.4. Recent initiatives
6. 8.6. miRagen Therapeutics, Inc.
  1. 8.6.1. Company Overview
  2. 8.6.2. miRagen Therapeutics, Inc. Sales, Revenue, Price, and Gross Margin
  3. 8.6.3. Product portfolio
  4. 8.6.4. Recent initiatives
7. 8.7. Gradalis, Inc
  1. 8.7.1. Company Overview
  2. 8.7.2. Gradalis, Inc Sales, Revenue, Price, and Gross Margin
  3. 8.7.3. Product portfolio
  4. 8.7.4. Recent initiatives
8. 8.8. Sirnaomics, Inc
  1. 8.8.1. Company Overview
  2. 8.8.2. Sirnaomics, Inc Sales, Revenue, Price, and Gross Margin
  3. 8.8.3. Product portfolio
  4. 8.8.4. Recent initiatives
9. 8.9. Arbutus Biopharma (Tekmira)
  1. 8.9.1. Company Overview
  2. 8.9.2. Arbutus Biopharma (Tekmira) Sales, Revenue, Price, and Gross Margin
  3. 8.9.3. Product portfolio
  4. 8.9.4. Recent initiatives
10. 8.10. Silence Therapeutics
  1. 8.10.1. Company Overview
  2. 8.10.2. Silence Therapeutics Sales, Revenue, Price, and Gross Margin
  3. 8.10.3. Product portfolio
  4. 8.10.4. Recent initiatives
11. 8.11. Benitec Biopharma
  1. 8.11.1. Company Overview
  2. 8.11.2. Benitec Biopharma Sales, Revenue, Price, and Gross Margin
  3. 8.11.3. Product portfolio
  4. 8.11.4. Recent initiatives
12. 8.12. Sylentis
  1. 8.12.1. Company Overview
  2. 8.12.2. Sylentis Sales, Revenue, Price, and Gross Margin
  3. 8.12.3. Product portfolio
  4. 8.12.4. Recent initiatives
13. 8.13. Silenseed LTD
  1. 8.13.1. Company Overview
  2. 8.13.2. Silenseed LTD Sales, Revenue, Price, and Gross Margin
  3. 8.13.3. Product portfolio
  4. 8.13.4. Recent initiatives
CHAPTER 9. RNAi for Therapeutic — Industry Analysis
1. 9.1. Introduction and Taxonomy
2. 9.2. RNAi for Therapeutic Market – Key Trends
  1. 9.2.1. Market Drivers
  2. 9.2.2. Market Restraints
  3. 9.2.3. Market Opportunities
3. 9.3. Value Chain Analysis
4. 9.4. Key Mandates and Regulations
5. 9.5. Technology Roadmap and Timeline
6. 9.6. RNAi for Therapeutic market – Attractiveness Analysis
  1. 9.6.1. By Product
  2. 9.6.2. By Application
  3. 9.6.3. By Sales Channel
  4. 9.6.4. By Region
CHAPTER 10. Raw Material analysis
1. 10.1. RNAi for Therapeutic Key Raw Material Analysis
  1. 10.1.1. Key Raw Materials
  2. 10.1.2. Price Trend of Key Raw Materials
2. 10.2. Key Suppliers of Raw Materials
3. 10.3. Proportion of Manufacturing Cost Structure
  1. 10.3.1. Raw Materials
  2. 10.3.2. Labor Cost
4. 10.4. Manufacturing Expenses Analysis of RNAi for Therapeutic
CHAPTER 11. Industrial Chain, Sourcing Strategy and Downstream Buyers
1. 11.1. RNAi for Therapeutic Industrial Chain Analysis
2. 11.2. Upstream Raw Materials Sourcing
  1. 11.2.1. Risk Mitigation:
  2. 11.2.2. Supplier Relationships:
  3. 11.2.3. Business Processes:
  4. 11.2.4. Securing the Product:
3. 11.3. Raw Materials Sources of RNAi for Therapeutic Major Manufacturers in 2016
4. 11.4. Downstream Buyers
5. 11.5. Distributors/Traders List
CHAPTER 12. Marketing Strategy Analysis, Distributors
1. 12.1. Marketing Channel
2. 12.2. Direct Marketing
3. 12.3. Indirect Marketing
4. 12.4. Marketing Channel Development Trend
5. 12.5. Economic/Political Environmental Change
CHAPTER 13. Report Conclusion
CHAPTER 14. Research Approach & Methodology
1. 14.1. Report Description
2. 14.2. Research Scope
3. 14.3. Research Methodology
  1. 14.3.1. Secondary Research
  2. 14.3.2. Primary Research
  3. 14.3.3. Models
    1. 14.3.3.1. Company Share Analysis Model
    2. 14.3.3.2. Revenue Based Modeling
    3. 14.3.3.3. Research Limitations
    List of Figures
    
    FIG. 1 Global RNAi for Therapeutic Market, 2016-2026 (USD Million)
    FIG. 2 Global RNAi for Therapeutic Market Share, by Product , 2016 & 2026 (USD Million)
    FIG. 3 Global RNAi for Therapeutic Market share, by Product , 2016 & 2026 (K Unit)
    FIG. 4 Global siRNA RNAi for Therapeutic Market, 2016-2026 (USD Million)
    FIG. 5 Global siRNA RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 6 Global miRNA RNAi for Therapeutic Market, 2016-2026 (USD Million)
    FIG. 7 Global miRNA RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 8 Global shRNA RNAi for Therapeutic Market, 2016-2026 (USD Million)
    FIG. 9 Global shRNA RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 10 Global RNAi for Therapeutic Market Share, by Application, 2016 & 2026 (USD Million)
    FIG. 11 Global RNAi for Therapeutic Market share, by Application, 2016 & 2026 (K Unit)
    FIG. 12 Global Cancer RNAi for Therapeutic Market, 2016-2026 (USD Million)
    FIG. 13 Global Cancer RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 14 Global Ocular Disorder RNAi for Therapeutic Market, 2016-2026 (USD Million)
    FIG. 15 Global Ocular Disorder RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 16 Global HBV RNAi for Therapeutic Market, 2016-2026 (USD Million)
    FIG. 17 Global HBV RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 18 Global Others RNAi for Therapeutic Market, 2016-2026 (USD Million)
    FIG. 19 Global Others RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 20 Global RNAi for Therapeutic Market Share, by Sales Channel, 2016 & 2026 (USD Million)
    FIG. 21 Global RNAi for Therapeutic Market share, by Sales Channel, 2016 & 2026 (K Unit)
    FIG. 22 Global Direct Channel RNAi for Therapeutic Market, 2016-2026 (USD Million)
    FIG. 23 Global Direct Channel RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 24 Global Distribution Channel RNAi for Therapeutic Market, 2016-2026 (USD Million)
    FIG. 25 Global Distribution Channel RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 26 Global RNAi for Therapeutic Market Share, by Region, 2016 & 2026
    FIG. 27 Global RNAi for Therapeutic Market Share, by Region, 2016 & 2026
    FIG. 28 North America RNAi for Therapeutic Market, 2016-2026
    FIG. 29 North America RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 30 U.S. RNAi for Therapeutic Market, 2016-2026
    FIG. 31 U.S. RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 32 Canada RNAi for Therapeutic Market, 2016-2026
    FIG. 33 Canada RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 34 Europe RNAi for Therapeutic Market, 2016-2026
    FIG. 35 Europe RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 36 Germany RNAi for Therapeutic Market, 2016-2026
    FIG. 37 Germany RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 38 France RNAi for Therapeutic Market, 2016-2026
    FIG. 39 France RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 40 U.K. RNAi for Therapeutic Market, 2016-2026
    FIG. 41 U.K. RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 42 Italy RNAi for Therapeutic Market, 2016-2026
    FIG. 43 Italy RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 44 Spain RNAi for Therapeutic Market, 2016-2026
    FIG. 45 Spain RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 46 Rest of Europe RNAi for Therapeutic Market, 2016-2026
    FIG. 47 Rest of Europe RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 48 Asia Pacific RNAi for Therapeutic Market, 2016-2026
    FIG. 49 Asia Pacific RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 50 China RNAi for Therapeutic Market, 2016-2026
    FIG. 51 China RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 52 Japan RNAi for Therapeutic Market, 2016-2026
    FIG. 53 Japan RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 54 India RNAi for Therapeutic Market, 2016-2026
    FIG. 55 India RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 56 South Korea RNAi for Therapeutic Market, 2016-2026
    FIG. 57 South Korea RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 58 South-East Asia RNAi for Therapeutic Market, 2016-2026
    FIG. 59 South-East Asia RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 60 Rest of Asia Pacific RNAi for Therapeutic Market, 2016-2026
    FIG. 61 Rest of Asia Pacific RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 62 Latin America RNAi for Therapeutic Market, 2016-2026
    FIG. 63 Latin America RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 64 Brazil RNAi for Therapeutic Market, 2016-2026
    FIG. 65 Brazil RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 66 Mexico RNAi for Therapeutic Market, 2016-2026
    FIG. 67 Mexico RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 68 Rest of Latin America RNAi for Therapeutic Market, 2016-2026
    FIG. 69 Rest of Latin America RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 70 The Middle-East and Africa RNAi for Therapeutic Market, 2016-2026
    FIG. 71 The Middle-East and Africa RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 72 GCC Countries RNAi for Therapeutic Market, 2016-2026
    FIG. 73 GCC Countries RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 74 South Africa RNAi for Therapeutic Market, 2016-2026
    FIG. 75 South Africa RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 76 Rest of Middle-East Africa RNAi for Therapeutic Market, 2016-2026
    FIG. 77 Rest of Middle-East Africa RNAi for Therapeutic Market, 2016-2026 (K Unit)
    FIG. 78 Global RNAi for Therapeutic production and revenue, 2016-2026 (USD Million) (K Unit)
    FIG. 79 North America RNAi for Therapeutic production and revenue, 2016-2026 (USD Million) (K Unit)
    FIG. 80 Europe RNAi for Therapeutic production and revenue, 2016-2026 (USD Million) (K Unit)
    FIG. 81 Asia Pacific RNAi for Therapeutic production and revenue, 2016-2026 (USD Million) (K Unit)
    FIG. 82 Latin America RNAi for Therapeutic production and revenue, 2016-2026 (USD Million) (K Unit)
    FIG. 83 Middle East and Africa RNAi for Therapeutic production and revenue, 2016-2026 (USD Million) (K Unit)
    FIG. 84 Competitor Market Share – Revenue
    FIG. 85 Competitor Market Share – Volume
    FIG. 86 Alnylam Pharmaceuticals Revenue and Growth Rate
    FIG. 87 Alnylam Pharmaceuticals Market Share
    FIG. 88 Arrowhead Pharmaceuticals, Inc Revenue and Growth Rate
    FIG. 89 Arrowhead Pharmaceuticals, Inc Market Share
    FIG. 90 Dicerna Pharmaceuticals, Inc Revenue and Growth Rate
    FIG. 91 Dicerna Pharmaceuticals, Inc Market Share
    FIG. 92 Quark Pharmaceuticals Revenue and Growth Rate
    FIG. 93 Quark Pharmaceuticals Market Share
    FIG. 94 RXi Pharmaceuticals Revenue and Growth Rate
    FIG. 95 RXi Pharmaceuticals Market Share
    FIG. 96 miRagen Therapeutics, Inc. Revenue and Growth Rate
    FIG. 97 miRagen Therapeutics, Inc. Market Share
    FIG. 98 Gradalis, Inc Revenue and Growth Rate
    FIG. 99 Gradalis, Inc Market Share
    FIG. 100 Sirnaomics, Inc Revenue and Growth Rate
    FIG. 101 Sirnaomics, Inc Market Share
    FIG. 102 Arbutus Biopharma (Tekmira) Revenue and Growth Rate
    FIG. 103 Arbutus Biopharma (Tekmira) Market Share
    FIG. 104 Silence Therapeutics Revenue and Growth Rate
    FIG. 105 Silence Therapeutics Market Share
    FIG. 106 Benitec Biopharma Revenue and Growth Rate
    FIG. 107 Benitec Biopharma Market Share
    FIG. 108 Sylentis Revenue and Growth Rate
    FIG. 109 Sylentis Market Share
    FIG. 110 Silenseed LTD Revenue and Growth Rate
    FIG. 111 Silenseed LTD Market Share
    FIG. 112 Market Dynamics
    FIG. 113 Global RNAi for Therapeutic – Value Chain Analysis
    FIG. 114 Key Mandates and Regulations
    FIG. 115 Technology Roadmap and Timeline
    FIG. 116 Market Attractiveness Analysis – By Product
    FIG. 117 Market Attractiveness Analysis – By Application
    FIG. 118 Market Attractiveness Analysis – By Sales Channel
    FIG. 119 Market Attractiveness Analysis – By Region
    FIG. 120 Manufacturing Cost Structure of RNAi for Therapeutic
    FIG. 121 RNAi for Therapeutic Industrial Chain Analysis
    FIG. 122 Market Channel
    FIG. 123 Marketing Channel Development Trend
    FIG. 124 Growth in World Gross Product, 2008-2018
    
    List of Tables
    
    TABLE 1 Global RNAi for Therapeutic market, 2016 & 2026 (USD Million)
    TABLE 2 Global RNAi for Therapeutic market, by Product , 2016-2026 (USD Million)
    TABLE 3 Global RNAi for Therapeutic market, by Product , 2016-2026 (K Unit)
    TABLE 4 Global RNAi for Therapeutic market, by Application, 2016-2026 (USD Million)
    TABLE 5 Global RNAi for Therapeutic market, by Application, 2016-2026 (K Unit)
    TABLE 6 Global RNAi for Therapeutic market, by Sales Channel, 2016-2026 (USD Million)
    TABLE 7 Global RNAi for Therapeutic market, by Sales Channel, 2016-2026 (K Unit)
    TABLE 8 Global RNAi for Therapeutic market, by region, 2016-2026 (USD Million)
    TABLE 9 Global RNAi for Therapeutic market, by region, 2016-2026 (K Unit)
    TABLE 10 North America RNAi for Therapeutic Market, by Product , 2016-2026 (USD Million)
    TABLE 11 North America RNAi for Therapeutic Market, by Product , 2016-2026 (K Unit)
    TABLE 12 North America RNAi for Therapeutic Market, by Application, 2016-2026 (USD Million)
    TABLE 13 North America RNAi for Therapeutic Market, by Application, 2016-2026 (K Unit)
    TABLE 14 North America RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (USD Million)
    TABLE 15 North America RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (K Unit)
    TABLE 16 Europe RNAi for Therapeutic Market, by Product , 2016-2026 (USD Million)
    TABLE 17 Europe RNAi for Therapeutic Market, by Product , 2016-2026 (K Unit)
    TABLE 18 Europe RNAi for Therapeutic Market, by Application, 2016-2026 (USD Million)
    TABLE 19 Europe RNAi for Therapeutic Market, by Application, 2016-2026 (K Unit)
    TABLE 20 Europe RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (USD Million)
    TABLE 21 Europe RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (K Unit)
    TABLE 22 Asia Pacific RNAi for Therapeutic Market, by Product , 2016-2026 (USD Million)
    TABLE 23 Asia Pacific RNAi for Therapeutic Market, by Product , 2016-2026 (K Unit)
    TABLE 24 Asia Pacific RNAi for Therapeutic Market, by Application, 2016-2026 (USD Million)
    TABLE 25 Asia Pacific RNAi for Therapeutic Market, by Application, 2016-2026 (K Unit)
    TABLE 26 Asia Pacific RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (USD Million)
    TABLE 27 Asia Pacific RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (K Unit)
    TABLE 28 Latin America RNAi for Therapeutic Market, by Product , 2016-2026 (USD Million)
    TABLE 29 Latin America RNAi for Therapeutic Market, by Product , 2016-2026 (K Unit)
    TABLE 30 Latin America RNAi for Therapeutic Market, by Application, 2016-2026 (USD Million)
    TABLE 31 Latin America RNAi for Therapeutic Market, by Application, 2016-2026 (K Unit)
    TABLE 32 Latin America RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (USD Million)
    TABLE 33 Latin America RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (K Unit)
    TABLE 34 The Middle-East and Africa RNAi for Therapeutic Market, by Product , 2016-2026 (USD Million)
    TABLE 35 The Middle-East and Africa RNAi for Therapeutic Market, by Product , 2016-2026 (K Unit)
    TABLE 36 The Middle-East and Africa RNAi for Therapeutic Market, by Application, 2016-2026 (USD Million)
    TABLE 37 The Middle-East and Africa RNAi for Therapeutic Market, by Application, 2016-2026 (K Unit)
    TABLE 38 The Middle-East and Africa RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (USD Million)
    TABLE 39 The Middle-East and Africa RNAi for Therapeutic Market, by Sales Channel, 2016-2026 (K Unit)
    TABLE 40 North America RNAi for Therapeutic Production, Consumption, Export, Import, 2015-2019
    TABLE 41 Europe RNAi for Therapeutic Production, Consumption, Export, Import, 2015-2019
    TABLE 42 Asia Pacific RNAi for Therapeutic Production, Consumption, Export, Import, 2015-2019
    TABLE 43 Latin America RNAi for Therapeutic Production, Consumption, Export, Import, 2015-2019
    TABLE 44 Middle East & Africa RNAi for Therapeutic Production, Consumption, Export, Import, 2015-2019
    TABLE 45 Global RNAi for Therapeutic Market - Company Revenue Analysis 2015-2019 (USD Million)
    TABLE 46 Global RNAi for Therapeutic Market - Company Revenue Share Analysis 2015-2019(%)
    TABLE 47 Global RNAi for Therapeutic Market - Company Volume Analysis 2015-2019 (K Unit)
    TABLE 48 Global RNAi for Therapeutic Market - Company Volume Share Analysis 2015-2019(%)
    TABLE 49 Acquisitions and Mergers
    TABLE 50 New Product/Service Launch
    TABLE 51 Research & Development Activities
    TABLE 52 Market Drivers
    TABLE 53 Market Restraints
    TABLE 54 Market Opportunities
    TABLE 55 Production Base and Market Concentration Rate of Raw Material
    TABLE 56 Key Suppliers of Raw Materials
    TABLE 57 Raw Materials Sources of RNAi for Therapeutic Major Manufacturers in 2016
    TABLE 58 Major Buyers of RNAi for Therapeutic
    TABLE 59 Distributors/Traders of RNAi for Therapeutic by Region

Industry Major Market Players

Alnylam Pharmaceuticals
Arrowhead
Dicerna Pharmaceuticals
Quark Pharmaceuticals
RXi Pharmaceuticals
miRagen Therapeutics
Gradalis
Sirnaomics